RNA-based gene treatment that targets brain support cells (glia)
Glia Exclusive Gene Therapy
['FUNDING_R21'] · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · NIH-11143050
A new RNA-based gene treatment aims to change gene activity only in brain support cells (glia) to help people with Alzheimer's, autism, mood disorders, and related brain conditions.
Quick facts
| Phase | ['FUNDING_R21'] |
|---|---|
| Study type | Nih_funding |
| Sex | All |
| Sponsor | UNIVERSITY OF PITTSBURGH AT PITTSBURGH (nih funded) |
| Locations | 1 site (PITTSBURGH, UNITED STATES) |
| Trial ID | NIH-11143050 on ClinicalTrials.gov |
What this research studies
Researchers plan to create synthetic modified RNAs called GliaRNAs that turn genes on or off specifically in microglia or astrocytes, the brain's support cells. They will design these RNAs to avoid immune reactions, control how long they act, and deliver them without viral vectors. Lab tests in cells and animal models will check whether the GliaRNAs reach the right glial cell types safely and produce the intended gene changes. This is early-stage research focused on building a platform that could later be adapted for different neurological diseases.
Who could benefit from this research
Good fit: People with conditions linked to glial dysfunction—such as Alzheimer’s disease, some forms of autism, chronic pain, or affective disorders—would be the eventual candidates for therapies based on this platform.
Not a fit: Patients whose conditions are not related to glial biology or who need immediate, proven treatments are unlikely to benefit from this early preclinical work.
Why it matters
Potential benefit: If successful, this approach could enable safer, cell-specific gene therapies that target harmful glial activity in Alzheimer's, autism, mood disorders, and other brain diseases.
How similar studies have performed: RNA-based and viral gene delivery methods have shown short-term success in other brain cell types, but glia-exclusive, nonviral delivery is largely novel and not yet proven.
Where this research is happening
PITTSBURGH, UNITED STATES
- UNIVERSITY OF PITTSBURGH AT PITTSBURGH — PITTSBURGH, UNITED STATES (ACTIVE)
Researchers
- Principal investigator: SHEMESH, OR — UNIVERSITY OF PITTSBURGH AT PITTSBURGH
- Study coordinator: SHEMESH, OR
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Conditions: Affective Disorders, Alzheimer disease dementia, Alzheimer syndrome